• CureVac BV (NASDAQ: CVAC) said its first-generation COVID-19 vaccine candidate had passed its first interim analysis, but it was not yet ready to share efficacy data.

  • The company said an independent Data Safety Monitoring Board found no safety concerns for the vaccine, dubbed CV2CoV.

  • “The trial will continue to collect sufficient data in order to conduct statistically significant efficacy analysis,” the company said in its statement.

  • The CureVac vaccine is based on mRNA technology, like the ones developed by Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) – BioNTech SE (NASDAQ: BNTX).

  • In its Q1 earnings release, the company said CV2CoV data readout from the pivotal Phase 2b/3 trial is expected in June 2021.

  • Price Action: CVAC shares are down 3.5% at $107.56 during the market session on the last check Tuesday.

See more from Benzinga

  • Click here for options trades from Benzinga

  • European Drug Regulator Supports Use Of Pfizer-BioNTech COVID-19 Vaccine In Adolescents: Reuters

  • India To Skip Local Trials for 'Well Established' COVID-19 Vaccines; Pfizer Shots May Arrive By July: Reuters

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.